缩写名/全名 |
CURR TOP MED CHEM
CURRENT TOPICS IN MEDICINAL CHEMISTRY |
||||||||||||||||
ISSN号 | 1568-0266 | ||||||||||||||||
研究方向 | 医学-医药化学 | ||||||||||||||||
影响因子 | 2015:2.9, 2016:2.561, 2017:3.374, 2018:3.442, 2019:3.218, | ||||||||||||||||
出版国家 | NETHERLANDS | ||||||||||||||||
出版周期 | Semimonthly | ||||||||||||||||
年文章数 | 187 | ||||||||||||||||
出版年份 | 2001 | ||||||||||||||||
是否OA | No | ||||||||||||||||
审稿周期(仅供参考) | 一般,3-8周 |
||||||||||||||||
录用比例 | 较难 | ||||||||||||||||
投稿链接 | http://benthamscience.com/journal/authors-guidelines.php?journalID=ctmc#top | ||||||||||||||||
投稿官网 | http://benthamscience.com/journal/index.php?journalID=ctmc | ||||||||||||||||
h-index | 104 | ||||||||||||||||
CiteScore |
|
||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1568-0266%5BISSN%5D | ||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Advances in In-silico B-cell Epitope Prediction. Author: Sun P1,2,3, Guo S1,2,3, Sun J1,2,3, Tan L1,2,3, Lu C1,2,3, Ma Z1,2,3. Journal: Curr Top Med Chem. 2019;19(2):105-115. doi: 10.2174/1568026619666181130111827. PubMed DOI |
2. | AO-BBO: A Novel Optimization Algorithm and Its Application in Plant Drug Extraction. Author: Lv B1, Chen J1, Liu B1, Dong C1. Journal: Curr Top Med Chem. 2019;19(2):139-145. doi: 10.2174/1568026619666181130140709. PubMed DOI |
3. | Biological Activities of Artemisinin Derivatives Beyond Malaria. Author: Liu X1,2, Cao J2, Huang G2,3, Zhao Q1, Shen J1. Journal: Curr Top Med Chem. 2019;19(3):205-222. doi: 10.2174/1568026619666190122144217. PubMed DOI |
4. | Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Author: Li Y1,2, Wang F1,3, Chen X1,3, Wang J1,3, Zhao Y1,3, Li Y1,3,4, He B1,3. Journal: Curr Top Med Chem. 2019;19(3):223-241. doi: 10.2174/1568026619666190122144949. PubMed DOI |
5. | Recent Progress in Machine Learning-based Prediction of Peptide Activity for Drug Discovery. Author: Wu Q1, Ke H2, Li D1, Wang Q1,3, Fang J1,3, Zhou J1. Journal: Curr Top Med Chem. 2019;19(1):4-16. doi: 10.2174/1568026619666190122151634. PubMed DOI |
6. | Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. Author: Zhang J1,2, Wang L3, You X3, Xian T2, Wu J3,4, Pang J1. Journal: Curr Top Med Chem. 2019;19(1):57-73. doi: 10.2174/1568026619666190125145836. PubMed DOI |
7. | Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer. Author: Bai Y1, Li W1, Wang T2, Ahmad D3, Cui G1. Journal: Curr Top Med Chem. 2019 Jan 25. doi: 10.2174/1568026619666190125145110. [Epub ahead of print] PubMed DOI |
8. | Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug Delivery. Author: Li Y1, Du L2, Wu C2, Yu B3, Zhang H1, An F2. Journal: Curr Top Med Chem. 2019;19(1):74-97. doi: 10.2174/1568026619666190125144621. PubMed DOI |
9. | Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals. Author: Diao W1, Cai H1, Chen L2, Jin X3, Liao X3, Jia Z1. Journal: Curr Top Med Chem. 2019;19(1):33-56. doi: 10.2174/1568026619666190201100739. PubMed DOI |
10. | Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors. Author: Liu N1,2, Wan Q1,2, Cheng Z3, Chen Y1,2. Journal: Curr Top Med Chem. 2019;19(1):17-32. doi: 10.2174/1568026619666190201094952. PubMed DOI |
|
|